Keeping Track: FDA Issues Three Four-Month Approvals: Ninlaro, Darzalex, And Narcan Nasal Spray
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Cost Concerns May Hinder Naloxone Co-Prescribing Ideas
US FDA estimates mandating naloxone co-prescriptions could dramatically increase spending to more than total estimated cost of opioid crisis itself; joint advisory committee to consider options to increase naloxone availability.
FDA’s Naloxone Product Approval Standards May See Changes
Advisory committees will weigh adequacy of current pharmacokinetic requirements and pediatric dosing for novel formulations of the opioid overdose reversal agent.
End Of US FDA’s Very Fast Reviews? 2022 Novel Approvals Stayed Close To PDUFA Timeframes
Moderation was a theme of the year in novel approvals, as CDER’s median review time rose for the first time in five years and even the center’s fastest approval took more than seven months. A Pink Sheet infographic breaks down which review pathways did the best last year.